Primary Pulmonary Hypertension (PPH) & Redux/ Pondimin Users

Medical research has shown that primary pulmonary hypertension (PPH) suffered in former Fen Phen, Redux, and Pondimin users will continue to increase because of the large underestimation of actual patients affected by this serious condition. The New England Journal of Medicine published a study showing that primary pulmonary hypertension normally occurs in 1 in 500,000 people but that it has appeared in 1 in 20,000 Fen Phen users.

American Home Products (AHP) found themselves in the middle of countless litigation due to the allegations that they were aware of their diet drugs Fen Phen, Redux, and Pondimin to cause primary pulmonary hypertension (PPH). The Redux lawsuits have found that AHP did not identify primary pulmonary hypertension (PPH) under the adverse reaction area of their diet drug’s label despite the European testing showing this to be a major concern.

The FDA later found evidence that AHP had miscoded primary pulmonary hypertension (PPH) reports and failing to have an official medical monitoring performed back in 1995. Still, labels were not changed on Fen Phen, Redux, and Pondimin until 62 people died, attributed to primary pulmonary hypertension (PPH) as the result of the diet drugs. Approved for the short-term use of the management of obesity, it was found that in as little as three months a twenty-three-fold increase in the risk of developing primary pulmonary hypertension (PPH) was present.

Developing primary pulmonary hypertension (PPH) is dangerous because it is often misdiagnosed due to attributing the common side effects to more typical complications. Common signs of PPH include, shortness of breath, chest pain, weakness, new heart murmur, fatigue, tiredness, fatigue, and death that doctors confuse for other indications. Years can go by without proper diagnosis, allowing the Redux/ Pondimin causing disease to progress into late stages.

A nationwide Class Action Settlement has been reached with manufacturer American Home Products that resolves the claims of former Pondimin and Redux patients suffering serious and fatal heart conditions, including primary pulmonary hypertension (PPH). On January 11, 2002, the Fen Phen settlement became final, entitling the estimated 6 to 7 million Americans that have taken Fen Phen eligible for compensation. If you have suffered primary pulmonary hypertension, or any other health complications due to the use of Fen Phen, Redux, or Pondimin, please contact us to learn more about your legal rights.